Trial Profile

Phase I Study of Single Agent Pembrolizumab (MK-3475) in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma (KEYNOTE 001)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Carcinoma; Malignant melanoma; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms KEYNOTE-001
Sponsors Merck Sharp & Dohme Corp.

20 Oct 2025 According to the Merck and Co Media Release, Edward B. Garon, MD, MS, professor of medicine, David Geffen School of Medicine, the University of California, Los Angeles, is the principal investigator for KEYNOTE-001.
20 Oct 2025 According to the Merck and Co Media Release, the 10-year analyses of KEYNOTE-001 and -010, were presented during a poster session at the European Society for Medical Oncology (ESMO) Congress 2025.
20 Oct 2025 Results presented in the Merck and Co Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com